Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson's disease.

Publisher: Wolters Kluwer Health, Medknow Country of Publication: India NLM ID: 101316351 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1673-5374 (Print) Linking ISSN: 16735374 NLM ISO Abbreviation: Neural Regen Res Subsets: PubMed not MEDLINE

Publication: 2013 - : Mumbai : Wolters Kluwer Health, Medknow
Original Publication: Shenyang : Editorial Board of Neural Regeneration Research

JOURNAL/nrgr/04.03/01300535-202502000-00033/figure1/v/2024-05-28T214302Z/r/image-tiff There is a need to develop interventions to slow or reverse the degeneration of dopamine neurons in Parkinson's disease after diagnosis. Given that preclinical and clinical studies suggest benefits of dietary n-3 polyunsaturated fatty acids, such as docosahexaenoic acid, and exercise in Parkinson's disease, we investigated whether both could synergistically interact to induce recovery of the dopaminergic pathway. First, mice received a unilateral stereotactic injection of 6-hydroxydopamine into the striatum to establish an animal model of nigrostriatal denervation. Four weeks after lesion, animals were fed a docosahexaenoic acid-enriched or a control diet for the next 8 weeks. During this period, the animals had access to a running wheel, which they could use or not. Docosahexaenoic acid treatment, voluntary exercise, or the combination of both had no effect on (i) distance traveled in the open field test, (ii) the percentage of contraversive rotations in the apomorphine-induction test or (iii) the number of tyrosine-hydroxylase-positive cells in the substantia nigra pars compacta. However, the docosahexaenoic acid diet increased the number of tyrosine-hydroxylase-positive terminals and induced a rise in dopamine concentrations in the lesioned striatum. Compared to docosahexaenoic acid treatment or exercise alone, the combination of docosahexaenoic acid and exercise (i) improved forelimb balance in the stepping test, (ii) decreased the striatal DOPAC/dopamine ratio and (iii) led to increased dopamine transporter levels in the lesioned striatum. The present results suggest that the combination of exercise and docosahexaenoic acid may act synergistically in the striatum of mice with a unilateral lesion of the dopaminergic system and provide support for clinical trials combining nutrition and physical exercise in the treatment of Parkinson's disease.
(Copyright © 2025 Copyright: © 2025 Neural Regeneration Research.)

J Parkinsons Dis. 2021;11(4):1491-1505. (PMID: 34250955)
J Parkinsons Dis. 2020;10(3):757-774. (PMID: 32741777)
Nutrients. 2019 Aug 16;11(8):. (PMID: 31426362)
Mov Disord. 2016 Jan;31(1):23-38. (PMID: 26715466)
Front Physiol. 2021 Sep 16;12:736905. (PMID: 34603087)
Parkinsonism Relat Disord. 2019 May;62:68-72. (PMID: 30722964)
Braz J Med Biol Res. 2018 Dec 10;52(1):e7830. (PMID: 30539969)
J Neurol Phys Ther. 2019 Jan;43(1):12-25. (PMID: 30531382)
Stroke. 2011 Oct;42(10):2903-9. (PMID: 21852616)
Mol Med Rep. 2018 Feb;17(2):3356-3363. (PMID: 29257290)
Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):247-50. (PMID: 18023566)
Sci Rep. 2015 Oct 29;5:15791. (PMID: 26511533)
Mol Neurobiol. 2019 Apr;56(4):2944-2951. (PMID: 30073506)
Mov Disord. 2016 Oct;31(10):1444-1454. (PMID: 27477046)
J Neurosci. 1995 May;15(5 Pt 2):3863-75. (PMID: 7751951)
Exp Neurol. 2009 Sep;219(1):208-11. (PMID: 19460369)
Neuroscience. 2018 May 21;379:292-301. (PMID: 29559387)
Mayo Clin Proc. 2018 Mar;93(3):360-372. (PMID: 29502566)
Prog Brain Res. 2020;252:61-89. (PMID: 32247375)
Neurology. 2020 Mar 17;94(11):481-494. (PMID: 32102975)
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1401-8. (PMID: 19632286)
Synapse. 2001 Jun 1;40(3):225-34. (PMID: 11304760)
PLoS One. 2019 Jun 10;14(6):e0218130. (PMID: 31181111)
Biomolecules. 2023 Jun 11;13(6):. (PMID: 37371557)
Front Neurol. 2019 Dec 10;10:1245. (PMID: 31920905)
JAMA Neurol. 2018 Feb 1;75(2):219-226. (PMID: 29228079)
Front Aging Neurosci. 2019 Feb 22;11:23. (PMID: 30853908)
Pharmacol Biochem Behav. 1980 Feb;12(2):185-8. (PMID: 7189592)
J Lipid Res. 2005 Oct;46(10):2299-305. (PMID: 16061957)
Curr Opin Clin Nutr Metab Care. 2018 Mar;21(2):71-77. (PMID: 29206690)
Neurotox Res. 2020 Dec;38(4):850-858. (PMID: 32803628)
Brain Res. 1970 Dec 18;24(3):485-93. (PMID: 5494536)
Oxid Med Cell Longev. 2017;2017:2138169. (PMID: 28713483)
Pharmacol Ther. 2021 Jun;222:107785. (PMID: 33310157)
Brain Res. 2010 Jun 23;1341:72-83. (PMID: 20116369)
BMC Neurol. 2015 Nov 19;15:236. (PMID: 26584951)
Trends Neurosci. 2003 Apr;26(4):215-21. (PMID: 12689773)
Neurobiol Dis. 2014 Mar;63:201-9. (PMID: 24316165)
Lancet. 2021 Jun 12;397(10291):2284-2303. (PMID: 33848468)
Curr Neuropharmacol. 2018 Mar 5;16(3):308-326. (PMID: 28901279)
Mov Disord. 2019 Jan;34(1):58-66. (PMID: 30653734)
Mov Disord. 2019 Jun;34(6):801-811. (PMID: 31091353)
Brain Res. 2002 Nov 1;954(1):32-41. (PMID: 12393230)
Int J Mol Sci. 2018 Feb 08;19(2):. (PMID: 29419747)
Nutrients. 2022 Oct 25;14(21):. (PMID: 36364733)
Ann N Y Acad Sci. 1992 May 11;648:71-86. (PMID: 1637074)
J Prev Alzheimers Dis. 2020;7(1):29-36. (PMID: 32010923)
FASEB J. 2008 Apr;22(4):1213-25. (PMID: 18032633)
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S123-7. (PMID: 24262162)
Pharmaceuticals (Basel). 2023 Jan 20;16(2):. (PMID: 37259303)
Curr Top Behav Neurosci. 2016;29:333-351. (PMID: 26728168)
Exp Neurol. 2018 Mar;301(Pt A):39-49. (PMID: 29229294)
Behav Pharmacol. 2019 Jun;30(4):291-310. (PMID: 30216234)
Prostaglandins Leukot Essent Fatty Acids. 2016 Nov;114:1-10. (PMID: 27926457)
J Lipid Res. 2017 Oct;58(10):2071-2081. (PMID: 28694298)
Int J Mol Sci. 2020 May 06;21(9):. (PMID: 32384696)
Neurochem Int. 2009 Dec;55(7):476-82. (PMID: 19442696)
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S42-5. (PMID: 20083005)
J Nutr Biochem. 2016 Apr;30:133-42. (PMID: 27012630)
J Nutr. 1998 Dec;128(12):2512-9. (PMID: 9868201)
Behav Brain Res. 2012 May 1;230(2):309-16. (PMID: 22178078)
Neuroscience. 2017 Sep 17;359:224-247. (PMID: 28754312)
Mov Disord. 2019 Jan;34(1):48-57. (PMID: 30306634)
Int J Mol Sci. 2022 Dec 19;23(24):. (PMID: 36555817)
Mov Disord. 2019 Dec;34(12):1891-1900. (PMID: 31584222)
Mov Disord. 2015 Sep 15;30(11):1442-50. (PMID: 26208210)
EBioMedicine. 2020 Sep;59:102883. (PMID: 32690472)
Eur J Prev Cardiol. 2018 Sep;25(13):1409-1415. (PMID: 29667433)
Eur J Epidemiol. 2022 Jun;37(6):603-613. (PMID: 35416636)
J Parkinsons Dis. 2019;9(3):501-515. (PMID: 31282427)
Neurochem Int. 2006 Apr;48(5):404-14. (PMID: 16442670)
Br J Pharmacol. 2011 Oct;164(4):1357-91. (PMID: 21486284)
J Lipid Res. 2011 Feb;52(2):263-71. (PMID: 21115966)
Mov Disord. 2018 Dec;33(12):1945-1950. (PMID: 30376184)
Physiol Res. 2019 Mar 6;68(1):17-24. (PMID: 30433804)
J Funct Morphol Kinesiol. 2021 May 31;6(2):. (PMID: 34072692)
Crit Rev Food Sci Nutr. 2017 Jan 2;57(1):212-223. (PMID: 25830700)
Mov Disord. 2018 Aug;33(8):1248-1266. (PMID: 29570866)
Behav Brain Res. 2005 Jul 1;162(1):1-10. (PMID: 15922062)
Neuron. 2004 Sep 2;43(5):633-45. (PMID: 15339646)
Int Rev Neurobiol. 2019;147:45-74. (PMID: 31607362)
Prog Neurobiol. 2019 Jan;172:2-22. (PMID: 30481560)
PLoS One. 2011 Feb 23;6(2):e17397. (PMID: 21383850)
Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6985-90. (PMID: 27298371)
Eur J Neurosci. 2011 Apr;33(7):1264-74. (PMID: 21375602)
Neuroscience. 2015 Jul 23;299:156-74. (PMID: 25943481)
Age Ageing. 2018 Mar 01;47(2):281-288. (PMID: 29136094)

Date Created: 20240531 Latest Revision: 20240814

20240814

PMC11317935

10.4103/NRR.NRR-D-23-00595

38819068